These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 28776468)

  • 41. Awareness of medication related falls and preferred interventions among the elderly.
    Loke MY; Yen Gan LL; Islahudin F
    Pak J Pharm Sci; 2018 Mar; 31(2):359-364. PubMed ID: 29618421
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacogenomics: historical perspective and current status.
    Charlab R; Zhang L
    Methods Mol Biol; 2013; 1015():3-22. PubMed ID: 23824846
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacogenetics-guided dose modifications of antidepressants.
    Seeringer A; Kirchheiner J
    Clin Lab Med; 2008 Dec; 28(4):619-26. PubMed ID: 19059066
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review.
    Phillips KA; Veenstra DL; Oren E; Lee JK; Sadee W
    JAMA; 2001 Nov; 286(18):2270-9. PubMed ID: 11710893
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Pharmacogenetics and prediction of side effects of drugs].
    Harrak M; Khabbal Y; Amarti A; El Hassouni M; Ouldim K
    Ann Biol Clin (Paris); 2014; 72(4):405-12. PubMed ID: 25119798
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacogenetics and adverse drug reactions.
    Meyer UA
    Lancet; 2000 Nov; 356(9242):1667-71. PubMed ID: 11089838
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Implications of pharmacogenetics in every-day practice].
    Gerloff T; Roots I
    Internist (Berl); 2005 Nov; 46(11):1270-7. PubMed ID: 16170512
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genetic susceptibility to adverse drug reactions.
    Pirmohamed M; Park BK
    Trends Pharmacol Sci; 2001 Jun; 22(6):298-305. PubMed ID: 11395158
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacogenomics of triazole antifungal agents: implications for safety, tolerability and efficacy.
    Amsden JR; Gubbins PO
    Expert Opin Drug Metab Toxicol; 2017 Nov; 13(11):1135-1146. PubMed ID: 29022838
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacogenetics of psychotropic drug response.
    Malhotra AK; Murphy GM; Kennedy JL
    Am J Psychiatry; 2004 May; 161(5):780-96. PubMed ID: 15121641
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Testing the effects of a pharmaceutical program on fall rates in older adults.
    Zanetos JM; Lux KM; Richardson LG
    J Nurses Prof Dev; 2014; 30(3):143-8. PubMed ID: 24845093
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.
    Ingelman-Sundberg M; Sim SC; Gomez A; Rodriguez-Antona C
    Pharmacol Ther; 2007 Dec; 116(3):496-526. PubMed ID: 18001838
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice.
    Manolopoulos VG
    Clin Chem Lab Med; 2007; 45(7):801-14. PubMed ID: 17617019
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The role of pharmacogenomics in adverse drug reactions.
    Cacabelos R; Cacabelos N; Carril JC
    Expert Rev Clin Pharmacol; 2019 May; 12(5):407-442. PubMed ID: 30916581
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Obstetric therapeutics-how pharmacogenetics may inform drug therapy for pregnant women in the future.
    Haas DM
    Obstet Gynecol Surv; 2013 Sep; 68(9):650-4. PubMed ID: 25102121
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The impact of pharmacogenetic testing in patients exposed to polypharmacy: a scoping review.
    Meaddough EL; Sarasua SM; Fasolino TK; Farrell CL
    Pharmacogenomics J; 2021 Aug; 21(4):409-422. PubMed ID: 34140647
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug treatment as a cause of falls in old age. A review of the offending agents.
    Campbell AJ
    Drugs Aging; 1991; 1(4):289-302. PubMed ID: 1794021
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Australian and New Zealand Society for Geriatric Medicine: position statement - frailty in older people.
    Hubbard R; Ng K;
    Australas J Ageing; 2015 Mar; 34(1):68-73. PubMed ID: 25735472
    [No Abstract]   [Full Text] [Related]  

  • 59. Avoidable drug-gene conflicts and polypharmacy interactions in patients participating in a personalized medicine program.
    Reynolds KK; Pierce DL; Weitendorf F; Linder MW
    Per Med; 2017 May; 14(3):221-233. PubMed ID: 29767587
    [TBL] [Abstract][Full Text] [Related]  

  • 60. How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping.
    Verbeurgt P; Mamiya T; Oesterheld J
    Pharmacogenomics; 2014 Apr; 15(5):655-65. PubMed ID: 24798722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.